SEC Form 4 · accession 0000899243-18-027358
ACADIA PHARMACEUTICALS INC · ACAD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen Davis
Officer — PRESIDENT AND CEO · Director
Period of report
Oct 15, 2018
Accepted (ET)
Oct 24, 2018 · 4:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001070494
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option(right to buy)F1 | $21.28 | Oct 15, 2018 | A | 95,000 | A | — | Oct 15, 2028 | Common Stock | 95,000 | 95,000 | D |
| Restricted Stock UnitsF2,F3 | — | Oct 15, 2018 | A | 23,750 | A | — | — | Common Stock | 23,750 | 23,750 | D |
Explanation of responses
- F125% of the shares subject to the Stock Option vest and become exercisable on October 15, 2019. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments.
- F2Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.
- F3The restricted stock units vest in four equal annual installments beginning October 15, 2019.